Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Selcodis Inc. is a dynamic player in the healthcare and biotechnology sector, renowned for its pioneering work in developing cutting-edge diagnostic tools and solutions. The primary purpose of Selcodis Inc. is to enhance the accuracy and efficiency of healthcare diagnostics, providing vital support to medical practitioners and researchers worldwide. Their comprehensive product line includes advanced molecular diagnostic systems, which are instrumental in detecting a wide array of genetic disorders and infectious diseases. By leveraging innovative technologies and continuous research, Selcodis Inc. impacts several critical areas such as oncology, genetics, and infectious disease management. The company's solutions are pivotal in facilitating early disease detection and personalized treatment plans, contributing significantly to improved patient outcomes and healthcare sustainability. Given its significant role in advancing medical diagnostics, Selcodis Inc. holds a substantial position in the life sciences market, driving progress through strategic partnerships, collaborations with research institutions, and expanding global reach. Established as a leader in innovation, the company remains committed to transforming the future of healthcare diagnostics.
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -€282K. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€0.00
▼ -100.0% YoY
Net Income (TTM)
-€473K
▼ -491.2% YoY
Op. Margin
—
ROIC
-0.65%
▼ -1.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€282K
▲ +33.5% YoY
Op. Cash Flow (TTM)
-€282K
▲ +33.5% YoY
Net Debt
€28M
Cash & Equiv.
€1K
Continue Research